Key result
Cytokeratin 18 (CK18) serves as a promising non-invasive biomarker for diagnosing NAFLD, particularly the NASH stage, and evaluating treatment efficacy.
Why the study?
Traditional diagnostic methods for NAFLD are limited by accuracy, cost, and security issues, highlighting the need for early detection and timely lifestyle interventions.
Does Cytokeratin 18 (CK18) testing improve the diagnosis and monitoring of nonalcoholic fatty liver disease (NAFLD) compared to traditional methods?
Does Cytokeratin 18 (CK18) testing improve the diagnosis and monitoring of nonalcoholic fatty liver disease (NAFLD) compared to traditional methods?
CK18 is a promising non-invasive biomarker for the early diagnosis and monitoring of NAFLD, particularly the NASH stage.
INTRODUCTION: Nonalcoholic fatty liver disease (NAFLD) is a common metabolism-related disease worldwide. Although studies have shown that some medications may be effective for treating NAFLD, they do not satisfy the medical requirements, and lifestyle changes are the most basic strategy. Thus, early detection of NAFLD and timely lifestyle interventions are highly important. AREAS COVERED: The traditional diagnostic methods for NAFLD are limited by accuracy, cost, and security issues. Cytokeratin 18 (CK18), which is a marker of apoptosis and overall cell death, is an excellent biomarker for NAFLD. Liver fat accumulation in NAFLD triggers the activation of caspases, which increases the CK18 cleavage and its release into the blood. CK18 can help diagnose different stages of NAFLD, especially the nonalcoholic steatohepatitis (NASH) stage. In evaluating the efficacy of the NAFLD treatment and predicting the risk of NAFLD-related diseases, CK18 plays a significant role. EXPERT OPINION: CK18 can non-invasively monitor the pathological conditions of NAFLD patients and provide new hope for the early diagnosis of NAFLD. Adding CK18 to the NAFLD diagnostic criteria that are widely used in clinical settings may be efficient for the detection of NAFLD and early effective intervention.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2024) conducted a review in Nonalcoholic fatty liver disease (NAFLD). Cytokeratin 18 (CK18) was evaluated. Cytokeratin 18 (CK18) serves as a promising non-invasive biomarker for diagnosing NAFLD, particularly the NASH stage, and evaluating treatment efficacy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: